Author's Reply to Ma et al.: "Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis".

IF 4.4 3区医学 Q2 ONCOLOGY

Targeted Oncology Pub Date : 2024-09-01 Epub Date: 2024-07-19 DOI:10.1007/s11523-024-01083-8

Brigida Anna Maiorano, Andrea Necchi, Massimo Di Maio

引用次数: 0

查看原文本刊更多论文

作者对 Ma 等人的回复："PARP抑制剂对BRCA或HRR基因突变的转移性前列腺癌患者的血液学毒性：系统回顾与安全性 Meta 分析》。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Targeted Oncology 医学-肿瘤学

CiteScore

8.40

自引率

3.70%

发文量

审稿时长

>12 weeks

期刊介绍： Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes: Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches. Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways. Current Opinion articles that place interesting areas in perspective. Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations. Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement. Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.